Survival benefit of adjuvant TACE for patients with hepatocellular carcinoma and child-pugh B7 or B8 after hepatectomy
Adjuvant TACE demonstrates the potential to significantly enhance the long-term prognosis of HCC patients with CP B7 or B8 following hepatectomy, particularly those with multiple tumors, large tumor size, macrovascular or microvascular invasion, and narrow resection margin. Hence, pTACE should be considered for patients at high risk of recurrence following thorough evaluation.
Authors
- Kai-Di Wang
- C. M. Du
- Liming Jin (ORCID: https://orcid.org/0000-0002-6695-7193)
- Fangqiang Wei (ORCID: https://orcid.org/0000-0003-0871-2275)
- Guo‐Liang Shen (ORCID: https://orcid.org/0000-0003-4665-3501)
- Zhen‐Yu Gao
- Wenjing Jia (ORCID: https://orcid.org/0000-0002-0940-3338)
- Junwei Liu (ORCID: https://orcid.org/0000-0002-2982-2628)
- Dongsheng Huang (ORCID: https://orcid.org/0000-0003-2724-9618)
- Chengwu Zhang (ORCID: https://orcid.org/0000-0003-0204-4069)
- Xiao‐Kun Huang
- Wenfeng Lu (ORCID: https://orcid.org/0000-0003-3768-5173)
- Zheng-Kang Fang
- Lei Liang
Institutions
- Zhejiang Chinese Medical University (CN)
- Second Military Medical University (CN)
- Wenzhou Medical University (CN)
- Zhejiang Provincial People's Hospital (CN)
- Eastern Hepatobiliary Surgery Hospital (CN)
- Hangzhou Medical College (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-10-08
- DOI
- https://doi.org/10.1186/s12885-024-13028-5
- Citations
- 6
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 2.22
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
- Science and Technology Program of Zhejiang Province